Filtered By:
Cancer: Synovial Sarcoma
Drug: Actemra
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
1182PDA novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumour responses in synovial sarcoma patients
ConclusionsThe affinity-enhanced NY-ESO-1/TCR-T cell transfer exhibited early-onset CRS in association with in vivo cell proliferation and sequential tumor responses in the patients with high-NY-ESO-1-expressing synovial sarcoma.Clinical trial identificationNCT02366546.Legal entity responsible for the studyThe authors.FundingJapan Agency for Medical Research and Development.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
